LIXT.NASDAQLixte Biotechnology Holdings, INC
S-1/A: Lixte Biotechnology Holdings Seeks $4 Million in Unit Offering to Fund Cancer Therapy Development
Sentiment:
S-1/A Amendment to Registration Statement
Lixte Biotechnology Holdings is offering up to 1,895,734 units, each consisting of common stock or pre-funded warrants and common warrants, aiming to raise approximately $4 million for working capital and general corporate purposes, including advancing its cancer therapies.
Capital raiseLixte Biotechnology is offering up to 1,895,734 units, each consisting of common stock or pre-funded warrants and common warrants, aiming to raise approximately $4 million.The company intends to use the net proceeds from this offering for working capital and general corporate purposes.
Worse than expectedThe company has a history of operating losses and its auditor has expressed substantial doubt about its ability to continue as a going concern.
Summary
- Lixte Biotechnology Holdings, Inc. is conducting a public offering to sell up to 1,895,734 units, with each unit containing either one share of common stock or one pre-funded warrant, plus 1.25 common stock purchase warrants.
- The company aims to raise approximately $4 million in gross proceeds, assuming a public offering price of $2.11 per unit, which was the closing price of LIXT on October 31, 2024.
- The common warrants are immediately exercisable at a price equal to 110% of the offering price per unit and will expire five years from the issuance date.
- Investors can opt for pre-funded warrants instead of common stock in units to avoid exceeding a 4.99% beneficial ownership threshold, with the pre-funded warrants exercisable at $0.001 per share.
- WallachBeth Capital LLC is the exclusive placement agent for the offering, receiving a cash fee of 7.0% of the gross proceeds and reimbursement for certain expenses up to $75,000.
- The offering is expected to close no later than one business day following the commencement of sales, with a final termination date of November 30, 2024, unless terminated earlier at the company's discretion.
- The net proceeds will be used for working capital and general corporate purposes.
- The company is focusing on the clinical development of LB-100, a protein phosphatase 2A inhibitor, currently in clinical trials for various cancers.
- Lixte has a history of operating losses and its auditor has expressed substantial doubt about its ability to continue as a going concern.
- The company received an extension from Nasdaq to regain compliance with the minimum stockholders' equity rule by February 18, 2025.
Sentiment
Score: 5
Explanation: The document presents a mixed sentiment. While the company is actively pursuing clinical trials and has secured collaborations, it faces significant financial challenges, including a history of losses and doubts about its ability to continue as a going concern. The capital raise is necessary but also dilutive.
Positives
- The offering could provide Lixte Biotechnology with approximately $4 million in gross proceeds to fund its operations and clinical trials.
- The company has a lead compound, LB-100, in clinical development with potential for treating various cancers.
- Lixte has collaborations with reputable institutions like MD Anderson Cancer Center and the Netherlands Cancer Institute.
- The company has secured an exclusive patent license agreement with the National Institute of Health.
- Nasdaq has granted an extension for the company to regain compliance with listing requirements, providing additional time to improve its financial position.
Negatives
- Lixte Biotechnology has a history of operating losses and its auditor has expressed substantial doubt about its ability to continue as a going concern.
- The company needs significant additional financing to fund its operations and complete the development of LB-100.
- The offering is a 'reasonable best efforts' offering, meaning the company may not sell all the securities offered and may receive significantly less than the targeted $4 million.
- Investors in the offering will experience immediate and substantial dilution in the book value of their investment.
- The company is currently not in compliance with Nasdaq continued listing requirements and may be delisted if it fails to regain compliance.
Risks
- A clinical trial hold due to serious adverse events could delay or halt the development of the company's product candidate.
- The company may sell fewer than all of the securities offered, which would significantly reduce the amount of proceeds received.
- Investors in this offering will experience immediate and substantial dilution in the book value of their investment.
- The company's management will have broad discretion over the use of the proceeds and might not apply the proceeds in ways that increase the value of your investment.
- The company has a history of losses, expect to continue to incur losses in the near term and may not achieve or sustain profitability in the future.
- The company is currently not in compliance with the Nasdaq continued listing requirements and may be delisted.
- The common warrants and the pre-funded warrants are speculative in nature and there is not expected to be an active trading market for the common warrants.
- A possible short squeeze due to a sudden increase in demand of our shares of common stock that largely exceeds supply may lead to price volatility in our shares of common stock.
Future Outlook
The company intends to use the net proceeds from this offering for working capital and general corporate purposes. The company plans to continue the clinical development of LB-100 and explore strategic partnerships or licensing agreements.
Industry Context
Lixte Biotechnology operates in the competitive biopharmaceutical industry, focusing on cancer drug development. The company aims to enhance the effectiveness of existing cancer therapies through its protein phosphatase 2A inhibitors. The industry is characterized by high risks, long development timelines, and significant capital requirements.
Comparison to Industry Standards
- Lixte Biotechnology is a clinical-stage biopharmaceutical company, similar to companies like Veru Inc. and Agenus Inc., which are also focused on developing novel therapies for cancer.
- Compared to larger pharmaceutical companies like Roche and GSK, which are collaborating with Lixte in clinical trials, Lixte is a smaller company with limited resources and a higher risk profile.
- The company's focus on protein phosphatase 2A inhibitors is a unique approach, as most cancer therapies target other mechanisms such as kinases or immune checkpoints.
- The company's clinical trial designs, such as the randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma, are similar to those used by other companies in the industry.
- The company's reliance on collaborations and partnerships is a common strategy for smaller biopharmaceutical companies to share the costs and risks of drug development.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President and Chief Executive Officer | John S. Kovach | Bastiaan van der Baan | September 26, 2023 | Replacement |
| Chairman of the Board of Directors | Unknown | Bastiaan van der Baan | October 6, 2023 | Appointment |
Related Party Transactions
- The company's general and administrative costs include compensation to related parties, amounting to $1,718,180 in 2023 and $2,547,615 in 2022.
Stakeholder Impact
- Shareholders may experience dilution due to the public offering.
- Employees' job security is uncertain due to the company's financial challenges.
- Patients may benefit from the development of new cancer therapies.
- Suppliers and creditors face increased risk due to the company's going concern uncertainty.
Next Steps
- Complete the public offering and secure the targeted $4 million in gross proceeds.
- Continue clinical trials for LB-100 in various cancer indications.
- Regain compliance with Nasdaq listing requirements by February 18, 2025.
- Decide whether to proceed to a related Phase 2 portion of the study with the Spanish Sarcoma Group in the quarter ending December 31, 2024.
- Evaluate next steps for the clinical trial with the Netherlands Cancer Institute after the investigation of two Serious Adverse Events (SAEs).
Key Dates
| Date | Description |
|---|---|
| March 22, 2006 | Initial Cooperative Research and Development Agreement (CRADA) with the National Institute of Neurologic Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). |
| July 31, 2019 | Effective date of the Collaboration Agreement for an Investigator-Initiated Clinical Trial with the Spanish Sarcoma Group (Grupo Espaol de Investigacin en Sarcomas or GEIS). |
| March 9, 2021 | Initiation date of the Clinical Research Support Agreement with the City of Hope National Medical Center for a Phase 1b clinical trial of LB-100 combined with a standard regimen for small cell lung cancer. |
| October 13, 2022 | Announcement that the Spanish Agency for Medicines and Health Products (AEMPS) had authorized a Phase 1b/randomized Phase 2 study of LB-100 plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas (ASTS). |
| June 2, 2023 | Lixte effected a one-for-ten reverse split of its outstanding shares of common stock. |
| June 30, 2023 | The Phase 1 portion of the study with the Spanish Sarcoma Group began in the quarter ended June 30, 2023 to determine the recommended Phase 2 dose of the combination of doxorubicin and LB-100. |
| September 20, 2023 | Announcement of an investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 (PD-1) blocking antibody of GSK plc (GSK), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC). |
| September 26, 2023 | Bastiaan van der Baan replaced John S. Kovach as President and Chief Executive Officer. |
| October 5, 2023 | Dr. John S. Kovach passed away. |
| October 6, 2023 | Mr. van der Baan was appointed as Chairman of our Board of Directors. |
| January 29, 2024 | Announcement of the entry of the first patient into the MD Anderson Cancer Center clinical trial. |
| February 23, 2024 | Effective date of the Patent License Agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), each an institute or center of the National Institute of Health (NIH). |
| June 10, 2024 | Effective date of the Clinical Trial Agreement with the Netherlands Cancer Institute (NKI) to conduct a Phase 1b clinical trial of LB-100 combined with atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F. Hoffman-La Roche Ltd. (Roche), for patients with microsatellite stable metastatic colon cancer. |
| July 8, 2024 | Effective date of the termination of the Clinical Research Support Agreement with the City of Hope National Medical Center. |
| August 2024 | The clinical trial with the Netherlands Cancer Institute opened in August 2024 with the enrollment of the first patient. |
| August 19, 2024 | Receipt of a deficiency letter from Nasdaq indicating non-compliance with Nasdaq Listing Rule 5550(b)(1) (the Stockholders Equity Rule). |
| October 3, 2024 | Submission of a letter to Nasdaq with a plan to regain compliance with the Stockholders Equity Rule. |
| October 21, 2024 | Nasdaq provided notice that it had granted an extension through February 18, 2025 to regain compliance with the Stockholders Equity Rule. |
| October 31, 2024 | The closing price of LIXT on Nasdaq was $2.11 per share. |
| November 30, 2024 | The offering will end no later than November 30, 2024, unless we decide to terminate the offering earlier (which we may do at any time at our discretion) prior to that date. |
| December 31, 2026 | The clinical trial with the Spanish Sarcoma Group is expected to be completed and a report prepared by December 31, 2026. |
| December 31, 2027 | The MD Anderson Cancer Center clinical trial is currently expected to be completed by December 31, 2027. |
| February 18, 2025 | Deadline to complete capital raising initiatives and evidence compliance with the Stockholders Equity Rule through filing a Current Report on Form 8-K with the Securities and Exchange Commission (the SEC) providing certain required information. |
Keywords
Lixte Biotechnology, public offering, LB-100, cancer therapy, clinical trials, common stock, warrants, financing, biopharmaceutical, Nasdaq
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.